Effect of ezetimibe on plasma adipokines

a systematic review and meta-analysis

Eva Dolezelova, Evan Stein, Giuseppe Derosa, Pamela Maffioli, Petr Nachtigal, Amirhossein Sahebkar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. Methods: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI). Results: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95% CI –0.28, 0.96; P = 0.288), leptin (SMD –0.75, 95% CI: –2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD –1.06, 95% CI: –2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: –0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD –0.48, 95% CI –0.87, −0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. Conclusions: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.

Original languageEnglish
Pages (from-to)1380-1396
Number of pages17
JournalBritish Journal of Clinical Pharmacology
Volume83
Issue number7
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Adipokines
Meta-Analysis
Confidence Intervals
Tumor Necrosis Factor-alpha
Adiponectin
Plasminogen Activator Inhibitor 1
Therapeutics
Leptin
Ezetimibe
PubMed
Interleukin-6
Databases

Keywords

  • adipose tissue
  • cytokine
  • ezetimibe
  • pleiotropic
  • statin
  • tumour necrosis factor α

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effect of ezetimibe on plasma adipokines : a systematic review and meta-analysis. / Dolezelova, Eva; Stein, Evan; Derosa, Giuseppe; Maffioli, Pamela; Nachtigal, Petr; Sahebkar, Amirhossein.

In: British Journal of Clinical Pharmacology, Vol. 83, No. 7, 01.01.2017, p. 1380-1396.

Research output: Contribution to journalArticle

Dolezelova, Eva ; Stein, Evan ; Derosa, Giuseppe ; Maffioli, Pamela ; Nachtigal, Petr ; Sahebkar, Amirhossein. / Effect of ezetimibe on plasma adipokines : a systematic review and meta-analysis. In: British Journal of Clinical Pharmacology. 2017 ; Vol. 83, No. 7. pp. 1380-1396.
@article{edb5d2d08260467280dd218d9902869b,
title = "Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis",
abstract = "Aims: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. Methods: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95{\%} confidence interval (CI). Results: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95{\%} CI –0.28, 0.96; P = 0.288), leptin (SMD –0.75, 95{\%} CI: –2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD –1.06, 95{\%} CI: –2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95{\%} CI: –0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD –0.48, 95{\%} CI –0.87, −0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. Conclusions: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.",
keywords = "adipose tissue, cytokine, ezetimibe, pleiotropic, statin, tumour necrosis factor α",
author = "Eva Dolezelova and Evan Stein and Giuseppe Derosa and Pamela Maffioli and Petr Nachtigal and Amirhossein Sahebkar",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/bcp.13250",
language = "English",
volume = "83",
pages = "1380--1396",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Effect of ezetimibe on plasma adipokines

T2 - a systematic review and meta-analysis

AU - Dolezelova, Eva

AU - Stein, Evan

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

AU - Nachtigal, Petr

AU - Sahebkar, Amirhossein

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aims: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. Methods: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI). Results: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95% CI –0.28, 0.96; P = 0.288), leptin (SMD –0.75, 95% CI: –2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD –1.06, 95% CI: –2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: –0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD –0.48, 95% CI –0.87, −0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. Conclusions: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.

AB - Aims: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. Methods: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI). Results: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95% CI –0.28, 0.96; P = 0.288), leptin (SMD –0.75, 95% CI: –2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD –1.06, 95% CI: –2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: –0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD –0.48, 95% CI –0.87, −0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. Conclusions: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.

KW - adipose tissue

KW - cytokine

KW - ezetimibe

KW - pleiotropic

KW - statin

KW - tumour necrosis factor α

UR - http://www.scopus.com/inward/record.url?scp=85014748139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014748139&partnerID=8YFLogxK

U2 - 10.1111/bcp.13250

DO - 10.1111/bcp.13250

M3 - Article

VL - 83

SP - 1380

EP - 1396

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 7

ER -